Triptans in migraine
The risks of stroke, cardiovascular disease, and death in practice
Abstract
Background: Triptans are widely used to treat migraine but have been associated with stroke, myocardial infarction (MI), and ischemic heart disease (IHD) in case reports.
Objective: To estimate the incidence of stroke, cardiovascular events, and death in a migraine cohort, stratified by triptan prescription, and investigate whether the risk of these events was increased in those treated with triptans.
Methods: Migraine patients and matched nonmigraine control subjects were identified from the General Practice Research Database. Computerized records were searched for triptan prescriptions, stroke, TIA, MI, IHD, death, arrhythmia, and confounding variables. Incidence rates were calculated and migraine groups compared with controls using a Cox model, adjusting for confounders.
Results: Of 63,575 migraine patients, 13,664 were prescribed a triptan. There was no association between triptan prescription and stroke (hazard ratio [HR] 1.13; 95% CI 0.78, 1.65), MI (HR 0.93; 95% CI 0.60, 1.43), or other outcomes studied. The larger group of migraine patients not prescribed a triptan had an increased risk of stroke (HR 1.51; 95% CI 1.26, 1.82) and IHD (HR 1.35; 95% CI 1.18, 1.54) and a decreased risk of all-cause mortality (HR 0.72; 95% CI 0.65, 0.80).
Conclusions: In general practice, triptan treatment in migraine does not increase the risk of stroke, MI, cardiovascular death, IHD, or mortality. Triptans are prescribed to those less at risk of these events.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
File (hall.doc)
- Download
- 35.50 KB
References
1.
Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994; 34 (suppl 2): 6–11.
2.
Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the Physicians’ Health Study. Arch Neurol. 1995; 52: 129–134.
3.
Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol. 1997; 54: 362–368.
4.
Tzourio C, Iglesias S, Hubert JB, et al. Migraine and risk of ischaemic stroke: a case-control study. Br Med J. 1993; 307: 289–292.
5.
Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. Associated risk factors. JAMA. 1975; 231: 718–722.
6.
Bogousslavsky J, Regli F, Van Melle G, Payot M, Uske A. Migraine stroke. Neurology. 1988; 38: 223–227.
7.
Rothrock JF, Walicke P, Swenson MR, Lyden PD, Logan WR. Migrainous stroke. Arch Neurol. 1988; 45: 63–67.
8.
Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Théroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med. 1981; 304: 763–766.
9.
Nakamura Y, Shinozaki N, Hirasawa M, et al. Prevalence of migraine and Raynaud’s phenomenon in Japanese patients with vasospastic angina. Jpn Circ J. 2000; 64: 239–242.
10.
Leviton A, Malvea B, Graham JR. Vascular diseases, mortality, and migraine in the parents of migraine patients. Neurology. 1974; 24: 669–672.
11.
Merikangas KR. Comorbidity of migraine and other conditions in the general population of adults in the United States. Cephalalgia. 1991; (suppl 11): 108–109.Abstract.
12.
Mitchell P, Wang JJ, Currie J, Cumming RG, Smith W. Prevalence and vascular associations with migraine in older Australians. Aust NZ J Med. 1998; 28: 627–632.
13.
Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology. 1995; 45: 2135–2142.
14.
MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol. 1992; 34: 541–546.
15.
MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993; 87: 401–405.
16.
Dodick DW, Silberstein S, Dahlof CG. Is there a preferred triptan? Headache. 2002; 42: 1–7.
17.
Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet. 1994; 344: 985–986.
18.
Foster JM, Houghton LA, Whorwell PJ, Morris J. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther. 1999; 13: 927–936.
19.
Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet. 1994; 343: 1105–1106.
20.
Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med. 1995; 21: 82–83.
21.
O’Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology. 1995; 45: 2274–2276.
22.
Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache. 1996; 36: 329–331.
23.
Abbrescia VD, Pearlstein L, Kotler M. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopath Assoc. 1997; 97: 162–164.
24.
Laine K, Raasakka T, Mäntynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999; 39: 511–512.
25.
O’Quinn S, Davis RL, Gutterman DL, Pait GD, Fox AW. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia. 1999; 19: 223–231.
26.
Hall GC, Luscombe D, Walker SR. Post-marketing surveillance using a computerised general practice database. Pharm Med. 1988; 2: 345–351.
27.
Garcia Rodriguez LA, Perez Gutthan S. Use of the General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45: 419–425.
28.
The Read Codes, version 3. London: HMSO, 1996.
29.
Oxmis Problem Codes for Primary Medical Care. Oxford: Oxmis Publications, 1978.
30.
Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161: 5–8.
31.
International Statistical Classification of Diseases and Related Health Problems, 10th rev, vol 2. Geneva: World Health Organization, 1993.
32.
Stata statistical software [computer program]. College Station, TX. Stata Corp.
33.
Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 (suppl 7): 1–96.
34.
Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. Br Med J. 1995; 310: 830–833.
35.
Chang CL, Donaghy M, Poulter N, et al. Migraine and stroke in young women: case-control study. Br Med J. 1999; 318: 13–18.
36.
Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol. 1989; 42: 773–780.
37.
Carolei A, Marini C, De Matteis G, et al. History of migraine and risk of cerebral ischaemia in young adults. Lancet. 1996; 347: 1503–1506.
38.
Olesen J, Friberg L, Olsen TS, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain. 1993; 116: 187–202.
39.
Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke. 1999; 30: 1230–1233.
40.
Senter HJ, Lieberman AN, Pinto R. Cerebral manifestations of ergotism. Report of a case and review of the literature. Stroke. 1976; 7: 88–92.
41.
Lafitte C, Even C, Henry–Lebras F, de Toffol B, Autret A. Migraine and angina pectoris by coronary artery spasm. Headache. 1996; 36: 332–334.
42.
Wayne VS. A possible relationship between migraine and coronary artery spasm. Aust NZ J Med. 1986; 16: 708–710.
43.
Waters WE, Campbell MJ, Elwood PC. Migraine, headache, and survival in women. Br Med J. 1983; 287: 1442–1443.
44.
Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992; 267: 64–69.
45.
Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992; 152: 1273–1278.
46.
Dowson A, Jagger S. The UK migraine patient survey: quality of life and treatment. Curr Med Res Opin. 1999; 15: 241–253.
47.
Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998; 38: 87–96.
48.
Velez Roa S, Preumont N, Mols P, Stoupel E, Renard M. Ventricular fibrillation secondary to ergotamine in a healthy young woman. Acta Cardiol. 1999; 54: 283–286.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: June 20, 2003
Accepted: October 28, 2003
Published online: February 23, 2004
Published in print: February 24, 2004
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- 5-HT1B receptor activation produces rapid antidepressant-like effects in rodents, Pharmacology Biochemistry and Behavior, 247, (173917), (2025).https://doi.org/10.1016/j.pbb.2024.173917
- Migraine and Stroke: A Scoping Review, Journal of Clinical Medicine, 13, 18, (5380), (2024).https://doi.org/10.3390/jcm13185380
- Specifically formulated ketogenic, low carbohydrate, and carnivore diets can prevent migraine: a perspective, Frontiers in Nutrition, 11, (2024).https://doi.org/10.3389/fnut.2024.1367570
- Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1435208
- Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events, The Journal of Headache and Pain, 25, 1, (2024).https://doi.org/10.1186/s10194-024-01770-x
- International Headache Society global practice recommendations for the acute pharmacological treatment of migraine, Cephalalgia, 44, 8, (2024).https://doi.org/10.1177/03331024241252666
- Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery ( INP104 ) for the acute treatment of migraine , Headache: The Journal of Head and Face Pain, 64, 8, (983-994), (2024).https://doi.org/10.1111/head.14669
- Clinical guidance for choosing the right pharmacotherapy for migraine attacks, Expert Opinion on Pharmacotherapy, 25, 1, (37-44), (2024).https://doi.org/10.1080/14656566.2024.2303425
- Sumatriptan for Postcraniotomy Headache after Minimally Invasive Craniotomy for Clipping of Aneurysms: A Prospective Randomized Controlled Trial, Asian Journal of Neurosurgery, 19, 02, (250-255), (2024).https://doi.org/10.1055/s-0044-1786702
- Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease, Mayo Clinic Proceedings, 99, 11, (1722-1731), (2024).https://doi.org/10.1016/j.mayocp.2024.03.023
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.